Clinical Trial Update: Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of Gumarontinib in combination with a third EGFR-TKI for non-small cell lung cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gumarontinib

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING